Eric Mayoux

6.2k total citations · 5 hit papers
51 papers, 5.0k citations indexed

About

Eric Mayoux is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Eric Mayoux has authored 51 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Endocrinology, Diabetes and Metabolism, 28 papers in Molecular Biology and 21 papers in Surgery. Recurrent topics in Eric Mayoux's work include Diabetes Treatment and Management (32 papers), Pancreatic function and diabetes (21 papers) and Metabolism, Diabetes, and Cancer (13 papers). Eric Mayoux is often cited by papers focused on Diabetes Treatment and Management (32 papers), Pancreatic function and diabetes (21 papers) and Metabolism, Diabetes, and Cancer (13 papers). Eric Mayoux collaborates with scholars based in Germany, France and United States. Eric Mayoux's co-authors include Michael Mark, Ele Ferrannini, Volker Vallon, Hermann Koepsell, Maria Gerasimova, Scott C. Thomson, Takahiro Masuda, Timo Rieg, D. Charlemagne and Frédérique Scamps and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Circulation Research.

In The Last Decade

Eric Mayoux

49 papers receiving 4.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

2016 741 citations Michael Mark, Eric Mayoux et al. profile →
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

2017 402 citations Eric Mayoux et al. profile →
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice

2013 402 citations Eric Mayoux et al. profile →
Empagliflozin Increases Cardiac Energy Production in Diabetes

2018 293 citations Subodh Verma, Sonia Rawat et al. JACC Basic to Translational Science profile →
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition

2020 267 citations Issei Tomita, Shinji Kume et al. Cell Metabolism profile →

Peers

Countries citing papers authored by Eric Mayoux

Since Specialization

Citations

This map shows the geographic impact of Eric Mayoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Mayoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Mayoux more than expected).

Fields of papers citing papers by Eric Mayoux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Mayoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Mayoux. The network helps show where Eric Mayoux may publish in the future.

Co-authorship network of co-authors of Eric Mayoux

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Mayoux. A scholar is included among the top collaborators of Eric Mayoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Mayoux. Eric Mayoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition breakdown → 2020 ·Cell Metabolism ·Issei Tomita, Shinji Kume, Sho Sugahara, Norihisa Osawa, Kosuke Yamahara, Mako Yasuda‒Yamahara, Naoko Takeda, Masami Chin‒Kanasaki, Tatsuroh Kaneko, Eric Mayoux, Michael Mark, Motoko Yanagita, Hisakazu Ogita, Shin‐ichi Araki, Hiroshi Maegawa	267
2	Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat 2020 ·Cardiovascular Diabetology ·Sin‐Hee Park, (unknown), S. Gærtner, (unknown), (unknown), Hyun-Ho Lee, (unknown), Brigitte Pollet, Dominique Stéphan, Patrick Ohlmann, Jean‐Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel, Valérie B. Schini‐Kerth	99
3	Upregulation of sodium-glucose cotransporter 2 (SGLT2) expression in cultured senescent endothelial cells and in arterial sites at risk in vivo in rats 2018 ·Archives of Cardiovascular Diseases Supplements ·(unknown), (unknown), Noureddine Idris-Khodja, Lamia Amoura, Malak Abbas, Cyril Auger, Laurence Kessler, Eric Mayoux, Florence Toti, Valérie B. Schini‐Kerth	4
4	Empagliflozin Increases Cardiac Energy Production in Diabetes breakdown → 2018 ·JACC Basic to Translational Science ·Subodh Verma, Sonia Rawat, Kim L. Ho, Cory S. Wagg, Liyan Zhang, Hwee Teoh, (unknown), Golam M. Uddin, Gavin Y. Oudit, Eric Mayoux, Michael Lehrke, Nikolaus Marx, Gary D. Lopaschuk	293
5	The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes 2018 ·The Journal of Sexual Medicine ·Rana Assaly, Diane Gorny, Sandrine Compagnie, Eric Mayoux, Jacques Bernabé, Laurent Alexandre, François Giuliano, Delphine Behr‐Roussel	25
6	The effect of a single dose of Empagliflozin on cardiac energy status in diabetic mice 2017 ·Diabetes ·Desiree Abdurrachim, Emmy Manders, (unknown), (unknown), Eric Mayoux	1
7	Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes 2017 ·Cardiovascular Drugs and Therapy ·Nadjib Hammoudi, Dongtak Jeong, Rajvir Singh, (unknown), Michel Komajda, Eric Mayoux, Roger J. Hajjar, Djamel Lebeche	121
8	The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats 2017 ·Redox Biology ·Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller‐Schön, F. Ravandi Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel‐Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J. Lackner, Leszek Wojnowski, Serge P. Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel, Andreas Daiber	243
9	Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes 2017 ·Cardiovascular Diabetology ·Javad Habibi, Annayya R. Aroor, James R. Sowers, Guanghong Jia, Melvin R. Hayden, Mona Garro, Brady Barron, Eric Mayoux, R. Scott Rector, Adam Whaley‐Connell, Vincent G. DeMarco	205
10	Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation 2016 ·Journal of Pharmacology and Experimental Therapeutics ·Elisa Benetti, Raffaella Mastrocola, (unknown), Juan Carlos Cutrìn, Debora Nigro, Fausto Chiazza, Eric Mayoux, Massimo Collino, Roberto Fantozzi	79
11	OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS 2016 ·Journal of Hypertension ·Zaid Abassi, (unknown), Natalie Landa, Firas Younis, (unknown), Eric Mayoux, Lea Rath‐Wolfson, Talma Rosenthal	5
12	The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes 2016 ·PLoS ONE ·(unknown), Lihua Chen, (unknown), Eric Mayoux, Po Sing Leung	66
13	The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity 2014 ·PLoS ONE ·Matthias Oelze, Swenja Kröller‐Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mäder, Elena Zinßius, (unknown), Anna Gottschlich, Sebastian Steven, Eberhard Schulz, Serge P. Bottari, Eric Mayoux, Thomas Münzel, Andreas Daiber	260
14	The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Henrik H. Hansen, Jacob Jelsing, (unknown), Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein, Eric Mayoux	51
15	Alfuzosin Improves Penile Erection Triggered by Apomorphine in Spontaneous Hypertensive Rats 2003 ·European Urology ·Eric Mayoux	12
16	Effect of pressure overload on cardiac Ca2+ antagonist binding sites of guinea pig. Comparison with the adaptational response of the hypertrophied rat heart 1991 ·Cardiovascular Research ·(unknown), Eric Mayoux, Patrick Olivier, D. Charlemagne	8
17	Membrane proteins of the myocytes in cardiac overload. 1991 ·PubMed ·P. Mansier, B Chevalier, Eric Mayoux, D. Charlemagne, Luc Ollivier, (unknown), Bernard Swynghedauw	2
18	Membrane proteins of the myocytes in cardiac overload. 1990 ·British Journal of Clinical Pharmacology ·P. Mansier, B Chevalier, Eric Mayoux, D. Charlemagne, Luc Ollivier, (unknown), Bernard Swynghedauw	3
19	Adaptational Process of the Cardiac Ca2+ Channels to Pressure Overload 1988 ·Journal of Cardiovascular Pharmacology ·Eric Mayoux, (unknown), Bernard Swynghedauw, D. Charlemagne	34
20	Ca2+ channel antagonist receptors in normal and hypertrophied rat heart 1986 ·Journal of Molecular and Cellular Cardiology ·D. Charlemagne, Eric Mayoux, L. Lelièvre	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact